Life Science Competitiveness Indicators - GOV UK · 2016-11-23 · Life Science Competitiveness Indicators 4 Overview: Performance of UK Life Science Sector and Contribution to UK

Life Science Competitiveness Indicators 1

Life Science Competitiveness Indicators

March 2015


Preface

This report brings together in one place a set of competitiveness indicators covering a range of aspects of the life science environment in the UK and other countries. They are intended to give a broad understanding of the UK sector, and how it compares internationally.

The choice of these indicators was informed by Technical and Steering Groups made up of a range of life science sector stakeholders. These included representatives from trade associations, life science sector companies, research organisations, regulators and government bodies. Comparator countries have been selected on the basis of data availability, and advice from the Technical and Steering Groups as to the most appropriate comparators. In some instances where a comparison was considered desirable, it has not been possible as data for particular countries was not available or was not considered reliable.

There are a range of other UK specific data sources that were not used because internationally comparable data could not be identified. These limitations mean that, whilst this is the fullest picture we are currently able to provide, the set of indicators cannot be looked at in aggregate to provide an overall country ranking. Each indicator should be considered on its own merits and the caveats relating to data sources (which may be constantly updated) should be considered in each case. This report does not make any assessment of the relative importance of different factors for competitiveness, which is at least partly a subjective judgement.

For the most part, the data on which these indicators are based is drawn from already published data. Wherever possible a link is provided to the data, or to the publication from which the chart has been reproduced. In a few instances it has been necessary for data to be sourced commercially or obtained directly from the organisation holding it. In these cases the supplier is clearly credited against relevant charts. In cases where the data is from a proprietary source, we have not been able to reproduce the underlying data tables.

This is the first publication of these indicators. The intention is to further develop the indicator content and data sources for future publications.

We would like to thank all those who have contributed to these indicators, or supplied data for this publication.


Table of contents

Overview: Performance of UK Life Science Sector and Contribution to UK Economy 4

Overview: Competitiveness of UK Life Science Environment 5

Indicators for UK industry 6

Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations 7

Chart 1B: Number of people employed in manufacture of medical technology products 8

Chart 2A: Gross Value Added for pharmaceutical manufacturing in European competitor countries 9

Chart 2B: Gross Value Added for pharmaceutical manufacturing in UK 10

Chart 3A: Exports of pharmaceutical products 11

Chart 3B: Exports of medical technology products 12

Chart 4A: Imports of pharmaceutical products 13

Chart 4B: Imports of medical technology products 14

Chart 5A: Life sciences foreign direct investment projects 15

Chart 5B: Life sciences foreign direct investment – capital expenditure 16

Chart 6A: Share of global life science Initial Public Offerings (IPOs) – 2014 17

Chart 6B: Initial Public Offerings (IPOs) in life sciences – amount raised in 2014 (where known) 18

Chart 7A: Private equity investment – total investment 19

Chart 7B: Number of companies receiving private equity investment 20

Chart 8: Number of science graduates 21

Research and Development Indicators 22

Chart 9: Government spend on health research and development 23

Chart 10: 2013 non-industry spend on research and development 24

Chart 11: Pharmaceutical industry spend on research and development in the UK 25

Chart 12A: Share of life science academic citations 26

Chart 12B: Share of top 1% (most cited) life science citations 27

Regulatory Indicator 28

Chart 13: Instances where MHRA is in lead role in EU regulatory procedure 29

Clinical Research Indicators 30

Chart 14: Share of patients recruited to global studies (all trial phases) 31

Chart 15: Time from core package received to first patient enrolled in country (all trial phases) 32

Demand-side Indicators 33

Chart 16: Dashboard of NICE Technology Appraisal publication timeframes 34

Chart 17: Uptake of new medicines 35


Overview: Performance of UK Life Science Sector and Contribution to UK Economy

Chart 5B: Life sciences foreign direct investment – capital expenditure

2013

2012

2011

2010

2009

ItalySwitzerlandJapanFranceIrelandGermanyUKUnited States

0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2.0

Sp

end

in b

illio

ns o

f p

oun

ds

(£b

n)

Source: fDi Markets, from The Financial Times Ltd.

Notes: Values are for the year that projects were announced. Data is in current prices.

Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

2012

2011

2010

2009

2008

United KingdomNetherlandsItalyFranceSpainGermany

Num

ber

of

peo

ple

em

plo

yed

Source: Eurostat – Data Explorer, Annual detailed enterprise statistics for industry, http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=en

Notes: Selected Category in NACE_R2 “C21 Manufacture of basic pharmaceutical products and pharmaceutical preparations”. Data not available for some countries in certain years.

Chart 1B: Number of people employed in manufacture of medical technology products

20132012

2011

2010

2009

0

50,000

100,000

150,000

200,000

250,000

Num

ber

of

peo

ple

em

plo

yed

SwitzerlandUnitedKingdom

NetherlandsItalyFranceSpainGermany

Source: Eurostat – Data Explorer, Annual detailed enterprise statistics for industry, http://ec.europa.eu/eurostat/data/database

Notes: Categories in NACE_ R2 “C266 Manufacture of irradiation, electromedical and electrotherapeutic equipment” plus “C325 Manufacture of medical and dental instruments and supplies”. Data not available for some countries in certain years.

Chart 2B: Gross Value Added for pharmaceutical manufacturing in UK

0

5

10

15

201320122011201020092008200720062005

Gro

ss V

alue

Add

ed in

bill

ions

of p

ound

s (£

bn)

Source: : UK data from ONS National Accounts, The Blue Book 2014 Edition dataset time series “KKF7: mGDP manufacture of basic pharmaceutical products and pharmaceutical preparations” http://www.ons.gov.uk/ ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.html

Notes: UK data (Chart 2B) has been taken from a separate source from the comparator countries as it is not currently available broken down at this level through Eurostat. The medical technology sector is defined by two three-digit categories (C266 and C325) and National Accounts data is not available at this level. Data is in current prices.

http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.htmlhttp://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.htmlhttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=enhttp://ec.europa.eu/eurostat/data/database


Overview: Competitiveness of UK Life Science Environment

Chart 8: Number of science graduates

2012

2011

2010

2009

2008

2012

2011

2010

2009

2008

0

25,000

50,000

75,000

100,000

250,000

300,000

Uni

ted

Sta

tes

Uni

ted

Kin

gdom

Sw

itzer

land

Spa

in

Net

herla

nds

Japa

n

Italy

Irela

nd

Ger

man

y

Fran

ce

Bel

gium

Num

ber

of

gra

dua

tes 200,000

Source: United Nations Educational, Scientific and Cultural Organisation (UNESCO) http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DS

Notes: Data not available for some countries in certain years.

Chart 12B: Share of top 1% (most cited) life science citations

2012

2011

2010

2009

2008

UnitedStates

RussianFederation

JapanItalyUnitedKingdom

FranceGermanyChinaCanada

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

55%

60%

65%

70%

Sha

re o

f ci

tatio

ns

Source: International Comparative Performance of the UK Research Base – 2013 https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013

Notes: In cases of co-authorship, citations are allocated to all participating countries (so totals may be more than 100%).

Chart 9: Government spend on health research and development

USUKSpainJapanItalyGermany FranceBelgium

2012

2011

2010

2009

2008

Sp

end

in b

illio

ns o

f U

S d

olla

rs ($

bn)

– 2

005

pri

ces

0

1

2

3

4

25

30

35

40

Source: OECD Research & Development statistics http://stats.oecd.org/index.aspx?r=227797

Notes: Government budget appropriations or outlays on R&D in Health.

Chart 7A: Private equity investment – total investment

2013

2012

2011

2010

2009

0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2.0

UKSwitzerlandSpainItalyIrelandGermanyFrance

Tota

l pri

vate

eq

uity

inve

stm

ent

in b

illio

ns o

f E

uro

s (€

bn)

Source: European Private Equity & Venture Capital Association (EVCA) http://www.evca.eu/research/activity-data/annual-activity-statistics/]

Notes: Data is based on country of portfolio company. Data is in current prices.

http://www.evca.eu/research/activity-data/annual-activity-statistics/]http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DShttps://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013http://stats.oecd.org/index.aspx?r=227797


Indicators for UK industry


Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

2012

2011

2010

2009

2008

United KingdomNetherlandsItalyFranceSpainGermany

Num

ber

of

peo

ple

em

plo

yed

Source: Eurostat – Data Explorer, Annual detailed enterprise statistics for industry, http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=en

Notes: Selected Category in NACE_R2 “C21 Manufacture of basic pharmaceutical products and pharmaceutical preparations”. Data not available for some countries in certain years.

http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=en


Chart 1B: Number of people employed in manufacture of medical technology products

20132012

2011

2010

2009

0

50,000

100,000

150,000

200,000

250,000N

umb

er o

f p

eop

le e

mp

loye

d

SwitzerlandUnitedKingdom

NetherlandsItalyFranceSpainGermany

Source: Eurostat – Data Explorer, Annual detailed enterprise statistics for industry, http://ec.europa.eu/eurostat/data/database

Notes: Categories in NACE_ R2 “C266 Manufacture of irradiation, electromedical and electrotherapeutic equipment” plus “C325 Manufacture of medical and dental instruments and supplies”. Data not available for some countries in certain years.

http://ec.europa.eu/eurostat/data/database


Chart 2A: Gross Value Added for pharmaceutical manufacturing in European competitor countries

0

5.0

10.0

15.0

20.0

25.0

Netherlands

Italy

France

Spain

Germany

20122011201020092008200720062005

Gro

ss V

alue

ad

ded

in b

illio

ns o

f E

uro

s (€

bn)

Source: Comparator countries’ data from Eurostat National Accounts data http://ec.europa.eu/eurostat/web/national-accounts/data/database

Notes: UK data (Chart 2B) has been taken from a separate source from the comparator countries as it is not currently available broken down at this level through Eurostat. The medical technology sector is defined by two three-digit categories (C266 and C325) and National Accounts data is not available at that level. Data is in current prices.

http://ec.europa.eu/eurostat/web/national-accounts/data/database


Chart 2B: Gross Value Added for pharmaceutical manufacturing in UK

0

5

10

15

201320122011201020092008200720062005

Gro

ss V

alue

Ad

ded

in b

illio

ns o

f p

oun

ds

(£b

n)

Source: UK data from ONS National Accounts, The Blue Book 2014 Edition dataset time series “KKF7: mGDP manufacture of basic pharmaceutical products and pharmaceutical preparations” http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.html

Notes: UK data (Chart 2B) has been taken from a separate source from the comparator countries as it is not currently available broken down at this level through Eurostat. The medical technology sector is defined by two three-digit categories (C266 and C325) and National Accounts data is not available at this level. Data is in current prices.

http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.html


Chart 3A: Exports of pharmaceutical products

20132012

2011

2010

2009

0

10

20

30

40

50

60

70

USUK SwitzerlandSpainJapanItalyIrelandGermanyFranceBelgium

Exp

ort

s in

bill

ions

of

US

Do

llars

($b

n)

Source: UNCTAD STAT Data Center http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en

Notes: Categories used are [541] Medicinal and pharmaceutical products excluding 542, and [542] Medicaments including veterinary medicaments. Data is in current prices.

http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en


Chart 3B: Exports of medical technology products

20132012

2011

2010

2009


0

5

10

15

20

25

30

35E

xpo

rts

in b

illio

ns o

f U

S D

olla

rs ($

bn)


Notes: Categories used are [774] Electro-diagnostic apparatus for medical science etc. and [872] Instruments and appliances, n.e.s, for medical, etc. Data in current prices.



Chart 4A: Imports of pharmaceutical products

20132012

2011

2010

2009


0

10

20

30

40

50

60

70Im

po

rts

in b

illio

ns o

f U

S D

olla

rs ($

bn)


Notes: Categories used are [541] Medicinal and pharmaceutical products excluding 542, and [542] Medicaments including veterinary medicaments. Data is in current prices.



Chart 4B: Imports of medical technology products

20132012

2011

2010

2009


0

5

10

15

20

25

30Im

po

rts

in b

illio

ns o

f U

S D

olla

rs ($

bn)


Notes: Categories used are [774] Electro-diagnostic apparatus for medical science etc., and [872] Instruments and appliances, n.e.s, for medical, etc. Data is in current prices.



Chart 5A: Life sciences foreign direct investment projects

2013

2012

2011

2010

2009

0

20

40

60

80

100

120


Num

ber

of

fore

ign

dire

ct in

vest

men

t p

roje

cts

Source: fDi Markets, from The Financial Times Ltd.

Notes: Numbers are for the year that projects were announced.


Chart 5B: Life sciences foreign direct investment – capital expenditure

2013

2012

2011

2010

2009


0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2.0S

pen

d in

bill

ions

of

po

und

s (£

bn)

Source: fDi Markets, from The Financial Times Ltd

Notes: Values are for the year that projects were announced. Data is in current prices.


Chart 6A: Share of global life science Initial Public Offerings (IPOs) – 2014

US 71.7%

China Hong Kong 7.6%

China 6.7%

UK 4.1%

Sweden 2.7%

France 2.2%

Brazil 1.5%

New Zealand 1.0%

Other:Japan 0.9%South Korea 0.6%Singapore 0.5%Australia 0.2%Finland 0.2%Norway 0.1%

Source: S&P Capital IQ

Notes: Numbers refer to the country in which the IPO was launched, not the domicile of the IPO Company.


Chart 6B: Initial Public Offerings (IPOs) in life sciences – amount raised in 2014 (where known)

Am

ount

rais

ed in

mill

ions

of p

ound

s (£

m)

0

100

200

300

400

500

3,000

3,500

4,500

4,500

5,000

Norw

ay

Finlan

d

Austr

alia

Singa

pore

Sout

h Kor

eaJa

pan

New

Zeala

ndBr

azil

Franc

e

Swed

enUKChina

China

Hon

g Kon

gUS

Source: S&P Capital IQ

Notes: Values refer to the country in which the IPO was launched, not the domicile of the IPO Company.


Chart 7A: Private equity investment – total investment

2013

2012

2011

2010

2009

0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2.0

UKSwitzerlandSpainItalyIrelandGermanyFrance

Tota

l pri

vate

eq

uity

inve

stm

ent

in b

illio

ns o

f E

uro

s (€

bn)


Notes: Data is based on country of portfolio company. Data is in current prices.

http://www.evca.eu/research/activity-data/annual-activity-statistics/]


Chart 7B: Number of companies receiving private equity investment

2013

2012

2011

2010

2009

0

20

40

60

80

100

120

140

160

180

200

220N

umb

er o

f co

mp

anie

s

UKSwitzerlandSpain ItalyIrelandGermanyFrance


Notes: Data is based on country of portfolio company.

http://www.evca.eu/research/activity-data/annual-activity-statistics/]


Chart 8: Number of science graduates

2012

2011

2010

2009

2008

2012

2011

2010

2009

2008

0

25,000

50,000

75,000

100,000

250,000

300,000

Uni

ted

Sta

tes

Uni

ted

Kin

gdom

Sw

itzer

land

Spa

in

Net

herla

nds

Japa

n

Italy

Irela

nd

Ger

man

y

Fran

ce

Bel

gium

Num

ber

of

gra

dua

tes 200,000

Source: United Nations Educational, Scientific and Cultural Organisation (UNESCO) http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DS

Notes: Data not available for some countries in certain years.

http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DS


Research and Development Indicators


Chart 9: Government spend on health research and development

USUKSpainJapanItalyGermany FranceBelgium

2012

2011

2010

2009

2008

Sp

end

in b

illio

ns o

f U

S d

olla

rs ($

bn)

– 2

005

pri

ces

0

1

2

3

4

25

30

35

40

Source: OECD Research & Development statistics http://stats.oecd.org/index.aspx?r=227797

Notes: Government budget appropriations or outlays on R&D in Health.

http://stats.oecd.org/index.aspx?r=227797


Chart 10: 2013 non-industry spend on research and development

National Institute of Health and Research – £959m

Association of Medical ResearchCharities Member Charities – £1,294m

Medical Research Council – £767m

Source: Association of Medical Research Charities http://www.amrc.org.uk/sites/default/files/doc_lib/AMRC-annual-review-2013-14.pdf

Notes: Expenditure by Medical Research Council and National Institute of Health Research will also be captured by Indicator 9.

http://www.amrc.org.uk/sites/default/files/doc_lib/AMRC-annual-review-2013-14.pdf


Chart 11: Pharmaceutical industry spend on research and development in the UK

Sp

end

in b

illio

ns o

f p

oun

ds

(£b

n)

0

1

2

3

4

5

201320122011201020092008200720062005200420032002

Source: ONS BERD survey 2013 http://www.ons.gov.uk/ons/rel/rdit1/bus-ent-res-and-dev/2013/stb-berd-2013.html

Notes: Data is not available for medical technology industry spend. Data is in current prices.

http://www.ons.gov.uk/ons/rel/rdit1/bus-ent-res-and-dev/2013/stb-berd-2013.html


Chart 12A: Share of life science academic citations

2012

2011

2010

2009

2008

UnitedStates

RussianFederation



0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%S

hare

of

cita

tions

Source: International Comparative Performance of the UK Research Base –2013 https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013

https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013


Chart 12B: Share of top 1% (most cited) life science citations

2012

2011

2010

2009

2008

UnitedStates

RussianFederation



0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

55%

60%

65%

70%S

hare

of

cita

tions

Source: International Comparative Performance of the UK Research Base – 2013 https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013

Notes: In cases of co-authorship, citations are allocated to all participating countries (so totals may be more than 100%).

https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013


Regulatory Indicator


Chart 13: Instances where MHRA is in lead role in EU regulatory procedure

0

10%

20%

30%

40%

50%

60%

70%

UK Decentralised Procedures - Reference Member State

Scientific AdviceCo-ordinator

Centralised ProceduresRapporteur/Co-rapporteur

2014201320122011201020092008

Pro

po

rtio

n o

f to

tal c

ases

Source: Medicines and Healthcare Products Regulatory Agency

Notes: The chart illustrates the proportion of work the UK has undertaken in three key areas of European regulatory activity. As the work of the Medicines and Healthcare Products Regulatory Agency (MHRA) within the areas covered by these indicators is collaborative, no direct comparison with the other 27 Member States is made and the UK’s position in the leading role is shown as a percentage of all work undertaken.

Each new medicinal product seeking approval in Europe through the Centralised Procedure has a Rapporteur and a co-Rapporteur appointed by the European Medicines Agency (EMA) to lead the assessment process. The Decentralised Procedure requires the applicant company to select a Reference Member State (RMS) to lead the assessment of the medicine during the procedure.


Clinical Research Indicators


Chart 14: Share of patients recruited to global studies (all trial phases)

2012

2011

2010

2009

2008

Czech RepublicPolandFranceGermanyUSUK

Sha

re o

f p

atie

nts

recr

uite

d g

lob

ally

0%

5%

10%

15%

20%

25%

30%

35%

40%

Source: This material is reproduced under a licence from CMR International.

Notes: You may not copy or re-distribute this material in whole or in part without the written consent of CMR International.


Chart 15: Time from core package received to first patient enrolled in country (all trial phases)

2012

2011

2010

2009

2008

Czech RepublicPolandFranceGermanyUSUK

Day

s

0

50

100

150

200

250

300

Source: This material is reproduced under a licence from CMR International.

Notes: You may not copy or re-distribute this material in whole or in part without the written consent of CMR International. “Core package received” refers to receipt of final documentation relating to the clinical study by the local operating company or their representative.


Demand-side Indicators


Chart 16 Dashboard of NICE Technology Appraisal publication timeframes

Source: National Institute for Health and Care Excellence – Technology Appraisal Programme

Notes: MA: Marketing AuthorisationACD: Appraisal Consultation DocumentFAD: Final Appraisal DeterminationDials address forecast and actual timeframes for different stages of the NICE Technology Appraisal process. Full details of the process, including descriptions of the separate stages can be found on the NICE website (http://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance). Red and Green zones on dials relate to whether milestones have been attained within existing targets for NICE performance.

http://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidancehttp://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidancehttp://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidancehttp://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance


Chart 17 Uptake of new medicines

Year 1

11.4%

UK

up

take

per

hea

d/a

ll co

untr

y up

take

per

hea

d

0%

50%

100%

150%

200%

250%

300%

350%

Years from launch

Year 2

31.9%

Year 3

50.7%

Year 4

50.7%

Year 5

90.2%

Source: IMS Health, courtesy of the Office of Health Economics

Notes: The chart shows the per capita uptake of twenty-eight new medicines launched in the UK between 2007 to 2012 and approved (recommended or restricted) by NICE, compared to the average in a group of comparator countries (Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, New Zealand, Spain, Sweden, Switzerland, and USA). The vertical lines represent uptake of the medicines in their 1st, 2nd etc. years after launch. Thus medicines launched in 2012 will only appear in the ‘Year 1 from launch’ group, those launched in 2011 will appear in both the ‘Year 1 from launch’ and ‘Year 2 from launch’ groups and so on. The medicines launched in 2007 will appear in all five year groups.

The percentage number reported in each year is the median rate of uptake in the UK relative to the international average in that year; in other words half of the medicines have a higher UK relative rate of use, and half have a lower UK relative rate of use. A value below 100% means that the UK per capita consumption of the new medicine(s) is below the international average. For example, medicines in their 3rd year after launch (and subsequently approved by NICE) were used in the UK at a level which was on average 50.7% of the average usage in the comparator countries. Caution is required in the 5th year after launch as the median rate of uptake reported (90.2%) is based on only five data points (medicines) and is therefore highly sensitive to the choice of medicines included.

BIS/15/249

Life Science Competitiveness IndicatorsPrefaceTable of contentsOverview: Performance of UK Life Science Sector and Contribution to UK EconomyOverview: Competitiveness of UK Life Science EnvironmentIndicators for UK industryChart 1AChart 1BChart 2AChart 2BChart 3AChart 3BChart 4AChart 4BChart 5AChart 5BChart 6AChart 6BChart 7AChart 7BChart 8

Research and Development IndicatorsChart 9Chart 10Chart 11Chart 12AChart 12B

Regulatory IndicatorChart 13

Clinical Research IndicatorsChart 14Chart 15

Demand-side IndicatorsChart 16Chart 17

Documents

Life Science Competitiveness Indicators - GOV UK · 2016-11-23 · Life Science Competitiveness Indicators 4 Overview: Performance of UK Life Science Sector and Contribution to UK